Resources from the same session
1317MO - Updated study results of pelcitoclax (APG-1252) combined with osimertinib in patients (pts) with EGFR-mutant non-small cell lung cancer (NSCLC)
Presenter: Li Zhang
Session: Mini oral session 2 - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
1318MO - First-in-human study of ABBV-637, an EGFR-targeting BCL-XL–inhibiting antibody-drug conjugate combined with osimertinib (OSI) in relapsed/refractory, EGFR-mutated non-small cell lung cancer (NSCLC)
Presenter: Julia Rotow
Session: Mini oral session 2 - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
1320MO - Early evidence of efficacy in patients (pts) with non-small cell lung cancer (NSCLC) with HER2 exon20 insertion (ex20ins) mutations treated in a phase I study with BAY 2927088
Presenter: Herbert Ho Fung Loong
Session: Mini oral session 2 - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
Invited Discussant 1317MO, 1318MO and 1320MO
Presenter: Martin Reck
Session: Mini oral session 2 - NSCLC, metastatic
Resources:
Slides
Webcast
1319MO - Intracranial efficacy of HER3-DXd in patients with previously treated advanced EGFR-mutated NSCLC: Results from HERTHENA-Lung01
Presenter: Melissa Johnson
Session: Mini oral session 2 - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
1321MO - Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2 (ERBB2)-mutant (HER2m) metastatic non–small cell lung cancer (NSCLC) with and without brain metastases (BMs): Pooled analyses from DESTINY-Lung01 and DESTINY-Lung02
Presenter: David Planchard
Session: Mini oral session 2 - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
1324MO - CNS outcomes of lazertinib vs gefitinib in EGFR-mutated advanced NSCLC: A LASER301 subset analysis
Presenter: Ross Soo
Session: Mini oral session 2 - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
Invited Discussant 1319MO, 1321MO and 1324MO
Presenter: Jessica Lin
Session: Mini oral session 2 - NSCLC, metastatic
Resources:
Slides
Webcast
1322MO - Insights into tumour dissemination and progression using longitudinal Imaging and ctDNA in the TRACERx lung cancer study
Presenter: Wing Kin Liu
Session: Mini oral session 2 - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
LBA72 - DARWIN II: Deciphering anti-tumour response and resistance to immunotherapy with intratumour heterogeneity in NSCLC
Presenter: Crispin Hiley
Session: Mini oral session 2 - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast